Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

N/A(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06561061Phase 2Completed

Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)

Role: collaborator

NCT04750707Phase 3Completed

Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )

Role: lead

NCT04844099Phase 3Completed

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia

Role: collaborator

NCT03851783Not ApplicableCompleted

Solar Oxygen Study

Role: collaborator

NCT04726826Completed

Biomarkers of Mortality and Morbidity in Children Hospitalized With Fever

Role: collaborator

NCT00926003Not ApplicableCompleted

Computerized Cognitive Rehabilitation in Ugandan Children With HIV

Role: collaborator

NCT01640561Not ApplicableCompleted

Enhancing Ugandan HIV-Affected Child Development With Caregiver Training

Role: collaborator

NCT02910310Not ApplicableCompleted

Introduction of UBT for PPH Management in Three Countries

Role: collaborator

All 8 trials loaded